Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort

20 Jul 2018

Abstract excerpt

Recombinant adeno-associated virus (rAAV) vectors are a promising platform for in vivo gene therapy. The presence of neutralizing antibodies (Nab) against AAV capsids decreases cell transduction efficiency and is a common exclusion criterion for participation in clinical trials. Novel engineered capsids are being generated to improve gene delivery to the target cells and facilitate success of clinical trials;...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Herpesvirus Infections and Treatments
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30027761
DOI: 10.1089/hum.2018.098

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population CohortPMID 30027761Read ↗

Understanding AAV vector immunogenicity: from particle to patientSemantic proximity Read ↗

Adeno-Associated Virus Antibody Profiles in Newborns, Children, and AdolescentsSemantic proximity Read ↗

Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapiesSemantic proximity Read ↗

Humoral immune responses to AAV gene therapy in the ocular compartmentSemantic proximity Read ↗

Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler–Najjar SyndromeSemantic proximity Read ↗

Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After TrialSemantic proximity Read ↗

Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene TransferSemantic proximity Read ↗

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsSemantic proximity Read ↗

Higher Seroprevalence of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies Among Racial Minorities in the United StatesSemantic proximity Read ↗

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacsSemantic proximity Read ↗

Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapySemantic proximity Read ↗

Seroprevalence of binding and neutralizing antibodies against 18 adeno-associated virus types in patients with neuromuscular disordersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.